Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Auteurs : Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber Rd, Coates AS, Goldhirsch A, Thürlimann B, Regan MM
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 105-114

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

Auteurs : Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 174
Pages : 27-37

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Année : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.

Auteurs : Lambertini M, Viglietti G, de Azambuja E
Année : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 43-51

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Auteurs : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart-Gebhart M, Gnant M, Baselga J, de Azambuja E
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1226-1238

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Auteurs : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Année : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 169-177

PERSEPHONE - implications for clinical practice in 2019.

Auteurs : Pondé N, de Azambuja E
Année : 2019
Journal : Nat Rev Clin Oncol
Volume : 16
Pages : 663-664

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Auteurs : Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Tagliabue E
Année : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 1-9

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Auteurs : Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber Rd
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1507-1513

Oncofertility counselling in premenopausal women with HER2-positive breast cancer.

Auteurs : Lambertini M, Demeestere I, Viglietti G, de Azambuja E
Année : 2019
Journal : Oncotarget
Volume : 10
Pages : 926-929

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Auteurs : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Auteurs : Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart-Gebhart M
Année : 2019
Journal : Ther Adv Med Oncol
Volume : 11
Pages : 1758835919827714

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Auteurs : Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Daidone MG
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3887-3895

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Auteurs : Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber Rd, Dowsett M, Leyland-Jones B, Piccart-Gebhart M, de Azambuja E
Année : 2019
Journal : Anticancer Res
Volume : 39
Pages : 797-802

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Auteurs : Brandão M, Caparica R, Eiger D, de Azambuja E
Année : 2019
Journal : Ann Oncol
Volume : 30 Suppl 10
Pages : x27-x42

How I treat metastatic triple-negative breast cancer.

Auteurs : Caparica R, Lambertini M, de Azambuja E
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000504

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Auteurs : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart-Gebhart M, Loi S, de Azambuja E
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 103-114

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.

Auteurs : Curigliano G, de Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM
Année : 2019
Journal : Oncologist
Volume : 24
Pages : e1034-e1043

Denosumab in early-stage breast cancer.

Auteurs : Brandão M, Debiasi M, de Azambuja E
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : e234-e235

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).

Auteurs : Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 176
Pages : 607-615